Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 20/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3638300 | 1.00 | GHSR (0.86) | GHSR | |
| SCHEMBL3679085 | 0.95 | GHSR (0.84) | GHSR | |
| SCHEMBL3679082 | 0.95 | GHSR (0.84) | GHSR | |
| SCHEMBL3635035 | 0.93 | GHSR (0.81) | GHSR | |
| SCHEMBL3635033 | 0.93 | GHSR (0.81) | GHSR | |
| SCHEMBL3640066 | 0.92 | GHSR (1.00) | GHSR | |
| SCHEMBL3640068 | 0.92 | GHSR (1.00) | GHSR | |
| SCHEMBL4112844 | 0.91 | GHSR (0.83) | GHSR | |
| SCHEMBL3415956 | 0.90 | GHSR (0.86) | GHSR | |
| SCHEMBL3637819 | 0.90 | GHSR (0.84) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915149-B1 | NOVEL TRIAZOLE DERIVATIVES AS GHRELIN ANALOGUE LIGANDS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2018-10-10 | — | — | EP | claimed |
| US-8710089-B2 | Triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors | ZENTARIS GMBH (DE) | 2014-04-29 | — | — | US | claimed |
| US-20100331343-A1 | NOVEL TRIAZOLE DERIVATIVES AS GHRELIN ANALOGUE LIGANDS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | ZENTARIS GMBH (DE) | 2010-12-30 | — | — | US | claimed |
| US-7829724-B2 | Triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors | ZENTARIS GMBH (DE) | 2010-11-09 | — | — | US | claimed |
| US-20100093638-A1 | TREAMENT FOR CHEMICAL SUBSTANCE ADDICTION | ABUNON AB (SE) | 2010-04-15 | — | — | US | claimed |
| US-20090042905-A1 | TRIAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2009-02-12 | — | — | US | claimed |
| EP-1958631-A1 | Novel triazole derivatives as ligands of G-protein coupled receptors | AEterna Zentaris GmbH (DE) | 2008-08-20 | — | — | EP | claimed |
| US-20070208061-A2 | NOVEL TRIAZOLE DERIVATIVES AS GHRELIN ANALOGUE LIGANDS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | ZENTARIS GMBH (DE) | 2007-09-06 | — | — | US | claimed |
| EP-1757290-A1 | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors | Zentaris GmbH (DE) | 2007-02-28 | — | — | EP | claimed |
| US-20070037857-A1 | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors | ZENTARIS GMBH (DE) | 2007-02-15 | — | — | US | claimed |
| EP-1915149-B1 | NOVEL TRIAZOLE DERIVATIVES AS GHRELIN ANALOGUE LIGANDS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2018-10-10 | — | — | EP | disclosed |
| US-9156796-B2 | Benzoimidazole-carboxylic acid amide derivatives as APJ receptor modulators | SANOFI (FR) | 2015-10-13 | — | — | US | disclosed |
| US-9156796-B2 | Benzoimidazole-carboxylic acid amide derivatives as APJ receptor modulators | SANOFI (FR) | 2015-10-13 | — | — | US | disclosed |
| US-9133181-B2 | Substituted 6-(4-hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-9133181-B2 | Substituted 6-(4-hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-20070208061-A2 | NOVEL TRIAZOLE DERIVATIVES AS GHRELIN ANALOGUE LIGANDS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | ZENTARIS GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| EP-1757290-A1 | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors | Zentaris GmbH (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20070037857-A1 | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors | ZENTARIS GMBH (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037857-A1 | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors | ZENTARIS GMBH (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037857-A1 | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors | ZENTARIS GMBH (DE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208061-A2 | NOVEL TRIAZOLE DERIVATIVES AS GHRELIN ANALOGUE LIGANDS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | GIPR, GHSR, GPR119 | GHSR 2/4885 |
| US-20100331343-A1 | NOVEL TRIAZOLE DERIVATIVES AS GHRELIN ANALOGUE LIGANDS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | GIPR, GHSR, GPR119 | GHSR 2/4885 |
| US-20100093638-A1 | TREAMENT FOR CHEMICAL SUBSTANCE ADDICTION | GHSR, GHRHR, TRHR | GHSR 1/4885 |
| US-20070037857-A1 | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors | GIPR, GHSR, GPR119 | GHSR 2/4885 |
| US-20090042905-A1 | TRIAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR3, GRK3, GPR88 | GHSR 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.